VLP-based Vaccine Development Services for Coronavirus
Virus-like particle (VLP) is a polymeric nanostructure assembled from
natural viral structural proteins, but do not contain any genetic material.
The VLP consists of high-density displays of viral surface proteins and
is therefore a highly adaptable tool for a variety of applications, such
as delivery system, antibody development, and membrane protein expression.
During the coronavirus pandemic, Creative Biostructure rapidly integrated VLP-based vaccine development technologies and
various in-house coronavirus-related VLP products to facilitate the development
of methods for the prevention of this emerging infectious disease.
Brief Introduction to VLP-based Vaccine
Traditional vaccines are prepared with attenuated or inactivated virus
strains, however, VLPs lacking viral genomes can offer a much safer option.
VLPs are similar in structure to real viruses and do not contain any viral
genetic material, thus they are not infectious and have the potential to
trigger a powerful immune response. VLP-based vaccines are one of the emerging
vaccine technologies that produce effective and durable protection. VLP
provides a multivalent structure that can hold multiple copies of antigens
and can elicit a more effective immune response. VLPs can also ensure tissue-specific
targeting because they are derived from real viruses. These versatile and
stable nanoparticles show great adjuvant properties and can induce innate
immune responses. They can present both B-cell epitopes for antibody production
and T-cell epitopes for inducing effective cellular immune responses. To
date, several VLP-based vaccines have been licensed and commercialized,
and many are in clinical trials.
Figure 1. Immunogenic features of a virus-like particle (VLP). (Crisci
E.; et al . 2013)
VLP-based Vaccine Development Services for Coronavirus
Nowadays, for the SARS-CoV-2 infection, Creative Biostructure offers high-quality VLP-based vaccine development services to customers
in the academia, biotech/pharmaceutical industries around the world.
Our professional team has mastered a variety of VLP expression systems,
including but not limited to yeast, baculovirus expression system, and
mammalian cells. We can design and develop custom VLPs, and our
off-the-shelf VLP products
have been shown to present antigenic epitopes in their appropriate
conformation to induce effective humoral and cellular immune responses.
In addition, we offer a variety of in-house developed
VLP products of the family Coronaviridae
.
Creative Biostructure specializes in the formulation and innovation of VLP-based vaccines.
We utilized the most commonly used adjuvant aluminum salts in VLP-based
vaccine formulations to enhance the immunogenicity of antigens. And we
have made great efforts in the innovative development of VLP-based vaccines,
such as reducing the antigen dose, improving the immunogenicity, and improving
the stability of long-term storage.
If your coronavirus vaccine development project involves VLP technology,
please do not hesitate to contact us, our customer service representatives
are available 24 hours a day from Monday to Sunday. Our experienced scientists
will work closely with you to keep you informed of the progress of the
project and take all the objectives into consideration.
Contact us to discuss your project!
Reference
-
Crisci E.; et al . Virus-like particle-based vaccines for animal viral infections. Inmunología . 2013, 32(3): 102-116.
